Ascendis Pharma Opens Compassionate Use Program for TransCon™ PTH (palopegteriparatide) in Germany
Ascendis Pharma Opens Compassionate Use Program for TransCon™ PTH (palopegteriparatide) in Germany
MDxHealth Announces its Extraordinary General Shareholders’ Meeting
MDxHealth Announces its Extraordinary General Shareholders’ Meeting
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) — Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage…
NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) — Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage…
More than 60 percent of patients achieved an overall response and 45.5 percent of patients…
Regulated Information Leuven, Belgium, Boston, MA, US – June 5, 2023 – 07.00 PM CET – Oxurion NV (Euronext…
The Un-carrier helps Valmont capture mission-critical data in industry-first beyond visual line of sight (BVLOS)…
Snowflake’s fifth annual user conference will reveal how enterprises can bring generative AI to their…
HAYWARD, Calif.–(BUSINESS WIRE)–#BigPharma—The Board of Directors of Pharmatech Associates today announced the appointment of Sireesha…
HOUSTON–(BUSINESS WIRE)–APQC, the benchmarking and best practices research firm, has named eight organizations as recipients…
Introduces Hassle Free, Time-saving, In-Car Parking Payments Using Parkopedia’s Nationwide Live Parking Database FARMINGTON HILLS,…
Publication of a transparency notification received from Scorpiaux BV Liege, Belgium, 05 June 2023 –…
Publication of a transparency notification received from Scorpiaux BV Liege, Belgium, 05 June 2023 –…
At 16 months median follow-up, cilta-cel significantly improved progression-free survival compared to two standard of…
At 16 months median follow-up, cilta-cel significantly improved progression-free survival compared to two standard of…
WAKEFIELD, MA, June 05, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the…
WAKEFIELD, MA, June 05, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the…
Figure 1 Baseline versus 3-month PET scans Results confirm positive signal previously reported in the…
Figure 1 Baseline versus 3-month PET scans Results confirm positive signal previously reported in the…
ST. LOUIS, June 05, 2023 (GLOBE NEWSWIRE) — Defender Pharmaceuticals, Inc. (the “Company” or “Defender”),…
ST. LOUIS, June 05, 2023 (GLOBE NEWSWIRE) — Defender Pharmaceuticals, Inc. (the “Company” or “Defender”),…
Confirmatory data from Cohort 1 of the Phase 3 THOR study showed greater than four-month…